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Abstract.  Two substances possessing the ability to 
bind to diphtheria toxin (DT) were found to be present 
in a  membrane fraction from DT-sensitive Vero cells. 
One of these substances was  found on the basis  of its 
ability to bind DT and inhibit its cytotoxic effect. This 
inhibitory substance competitively inhibited the bind- 
ing of DT to  Veto cells.  However this inhibitor could 
not bind to CRM197,  the product of a  missense muta- 
tion in the DT gene, and did not inhibit the binding of 
CRM197  to  Vero cells.  Moreover, similar levels of the 
inhibitory activity were observed in membrane frac- 
tions from DT-insensitive mouse cells,  suggesting the 
inhibitor is not the DT receptor which is specifically 
present in DT-sensitive cells.  The second DT-binding 
substance was found in the same  Vero cell membrane 
preparation by assaying the binding of ~25I-labeled 
CRM197.  Such DT-binding activity could not be ob- 
served in membrane preparation from mouse L  cells. 
From competition studies using labeled DT and CRM 
proteins,  we conclude that this binding activity is due 
to the surface receptor for DT.  Treatment of these sub- 
stances with several enzymes revealed that the  inhibi- 
tor was  sensitive to certain RNases but resistant to 
proteases, whereas the DT receptor was resistant to 
RNase but sensitive to proteases.  The receptor was 
solubilized and partially purified by chromatography 
on CM-Sepharose column.  Immunoprecipitation and 
Western blotting analysis of the partially purified 
receptor revealed that a  14.5-kD protein is the DT 
receptor, or at least a component of it. 
D 
PHTHERIA toxin (DT) ~ is a cytotoxic protein which 
inhibits cellular protein synthesis (4, 40) in eukary- 
otes  by  catalyzing the  ADP-ribosylation  of EF-2, 
which results in its inactivation (9,  12).  The first step of in- 
toxication by DT is binding of the toxin to a susceptible cell. 
A specific receptor for DT is believed to be involved in this 
step (13, 43). Cells from a number of mammals including hu- 
mans and monkeys are sensitive to DT,  but mouse and rat 
cells are insensitive (29). Several lines of evidence show that 
the difference in sensitivity to DT between species is primar- 
ily determined by the presence or absence of a cell surface 
receptor (18, 28, 31, 48). However, this receptor has not been 
isolated. The toxins bound to cell surface are then internal- 
ized by endocytosis (33), and the toxins, or at least their A 
fragments, enter the cytoplasm to exert its effects. Like in the 
case of Semliki Forest virus (SFV) (11), intravesicular low 
pH is required for the penetration of the toxin into cytoplasm 
(6,  17, 20,  27, 36). 
Some information has been obtained on the biochemical 
properties of DT  receptor.  The treatment of DT-sensitive 
cells with some proteases or phospholipase C  reduces the 
sensitivity to DT (32),  whereas treatment with neuramini- 
dase increases the sensitivity (26).  Although these studies 
1. Abbreviations  used in this paper: CRMs, cross reacting  materials related 
to diphtheria toxin;  DT, diphtheria toxin. 
give a clue to the chemical nature of DT receptor, the possi- 
bility that extensive alteration of cell surface affecting the 
sensitivity of cells can not be neglected. Some of the most 
specific information on the DT receptor was obtained from 
immunoprecipitation studies, after surface iodination of DT- 
sensitive cells and addition of DT and anti-DT antibody to 
the cell lysates. A glycoprotein of 160 kD was shown to be 
associated with DT binding upon SDS-PAGE (35). However, 
this protein has not been isolated in biologically active form, 
thus it has been uncertain whether it has a function in the 
binding of DT to cells and/or its internalization. 
A strategy to isolate the DT receptor has been to explore 
its binding activity for DT in isolated membrane or using 
solubilized membrane fractions. It has been shown that there 
is a correlation between the amount of the association of la- 
beled toxin and the sensitivity of the cells to the toxin (28, 
31). However, the specific binding of labeled DT to isolated 
membrane  has  not  been  observed as  yet.  When  binding 
studies were performed with labeled toxin and an isolated 
membrane fraction (2) or with intact cells at relative high 
toxin concentrations (16),  a significant association of toxin 
with DT-insensitive cells was observed, and the amount of 
toxin associated with cells was similar for DT-insensitive and 
DT-sensitive cells. These results have led to the interpretation 
that DT-insensitive cells also bear DT receptors. 
In this paper we describe two DT-binding molecules that 
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substances is referred to as inhibitor, because it inhibited the 
cytotoxic effects of DT and it is found on both DT-sensitive 
cells and DT-insensitive cells. The other substance, which is 
the DT receptor, was found to bind to both DT and CRM197 
with high affinity and is present only on DT-sensitive cells. 
Using the CRM197 it was possible to identify the DT recep- 
tor as a  single protein band after SDS-PAGE. 
Materials and Methods 
Enzymes 
RNase A from bovine pancreas, RNase T1 from Aspergillus, DNase I from 
bovine pancreas, DNase II from bovine spleen and ¢t-chymotrypsin from 
bovine pancreas were  purchased from Sigma Chemical Co.  (St.  Louis, 
MO).  Nuclease PI  from Penicillium citrinum was obtained from Yamasa 
Shoyu Co. (Choshi, Japan). RNase T2 from Aspergillus orizae and RNase 
U2 from Ustilego sphaerogem were obtained from Sankyo Co. (Tokyo, Ja- 
pan).  Trypsin (TPCK-treated) was from Worthington Biochemical Corp. 
(Freehold,  NJ). 
Buffers 
PBS (150 mM NaCl, 2.7 mM KCI, 10 mM phosphate buffer, pH 7.2); Buffer 
A  (130  mM NaC1,  50 mM Hepes,  10 mM KC1, 0.5 mM CaCI2,  1 mM 
NAN3, 1 mg/ml BSA, pH 7.0); Buffer B (10 mM phosphate buffer, 30 mM 
13-D-octylglucoside,  pH 7.2); Buffer C (150 mM NaCI,  10 mM phosphate 
buffer, 20 I.tg/ml antipain, 20 lag/ml leupeptin,  10 I.tg/ml chymostatin, pH 
7.2);  Buffer  D  (130  mM NaCl,  50  mM MES  [2-(N-morpholino)ethane- 
sulfonic acid]  10 mM KC1, 0.5 mM CaCl2,  1 mM NAN3, 1 mg/ml BSA, 
pH 6.1). 
Assays of  Protein Content and RNA Content 
The protein contents of membranes were determined by microbiuret method 
(14) with BSA as standard. The protein contents of samples containing oc- 
tylglucoside were measured by the method described previously (38). The 
RNA contents of membranes were determined by orcinol reaction (24) as 
described previously (39).  The RNA content of samples containing octyl- 
glucoside was determined after removing the detergent by ethanol precipi- 
tation. 
DT and Related Proteins 
DT, CRM45, CRM176, CRM197, and CRM228 were produced as described 
previously (44).  The nicked form of CRM197 was prepared by treatment 
with trypsin (7). Fragment A of diphtheria toxin was purified from the cul- 
ture fluid of the C7(15-22) strain (45). 
Preparation of  Membranes from Cultured Cells 
Veto cells and other cultured cells were grown on plastic dishes (150-mm 
wide),  collected with rubber policemen, and stored at  -80°C  until use. 
Ehrlich ascites tumor cells were grown in and harvested from mouse abdo- 
men. The membrane fractions were obtained by an alkali-extraction method 
essentially as described by Thom (42).  In our study, cells were extracted 
with 20 mM borate buffer, pH 10.2, 2 mM EDTA, 1 mM phenylmethylsul- 
fonyl fluoride (PMSF). The plasma membrane-rich pellet were resuspended 
and repelleted twice in Buffer C. 
Inhibition of the Cytotoxicity  of DT 
Cytotoxicity of DT was measured by assaying the rate of protein synthesis 
in cultured cells as described previously (27).  The inhibitory activity, [I], 
was calculated by the following formula, 
(Ci  -  Ct)  ×  100, 
[1]  -  (Co  -  Ct) 
where Co is the radioactivity incorporated by cells without toxin without 
the inhibitor, Ct is the count incorporated by cells with toxin without the 
inhibitor, and Ci is the count incorporated by cells with both toxin and the 
inhibitor. We defined one unit of inhibitory activity as the amount which 
gives an  inhibitory  activity of 50  under  the assay conditions described 
above.  The  inhibitory  activity of samples containing octylglucoside was 
measured after removing the detergent by dialysis. 
Effect of the Inhibitor on the Binding of DT 
or CRMs to Vero Cells 
Indirect assay of binding of DT or CRMs was carried out using ~25I-labeled 
anti-DT monoclonal antibody as described previously (25). 
Solubilization of the Inhibitor  from Vero  Cell 
Membrane and Chromatography  on DEAE-Cellulose 
Veto cell membrane suspended in buffer C (15 ml containing 60 mg protein) 
was mixed with  15 ml of 10 mM phosphate buffer, pH 7.2, and with  1.2 
ml of 1 M octylglucoside, then the mixture was put on ice for 30 min, fol- 
lowed by centrifugation at 80,000 g for 60 min. The supernatant was applied 
to a DE52 (Whatman Inc., Clifton, NJ) column. The column was washed 
with Buffer B containing 0.2 M NaCI, and then eluted with a linear gradient 
of NaCI (0.2-0.7 M) in Buffer B.  The inhibitory activity of each fraction 
was assayed after dialysis. 
Treatment of the Inhibitor with Enzymes 
For treatment with nucleases, the inhibitor purified by DE52 chromatogra- 
phy (10 U of the inhibitory activity) was dialyzed against PBS, then incu- 
bated at 37°C for 1 h with each enzyme in the presence of 1 mg/ml BSA. 
For treatment with RNase U2 and DNase II, the enzyme reaction was car- 
ried out in the presence of 50 mM acetate buffer, pH 5.0. For treatment with 
protease, the dialyzed inhibitor and each enzyme were incubated at 37°C 
for 60 rain, and the reaction was stopped by addition of 1 mM PMSE  50 
U/ml aprotinin and 2  mg/ml BSA. 
Binding of p25I]CRM197 to Isolated Membranes 
Nicked  CRM197  was labeled  with  NaL25I using Enzymobeads (Bio-Rad 
Laboratories, Richmond, CA) as described (25). Membrane fractions were 
prepared from Vero cells or L cells by the alkali-extraction method. Mem- 
branes were  washed twice  and  resuspended with  Buffer D  by  repeated 
aspiration through a  26-gauge needle.  The binding reaction was carried 
out in a  200  ~tl  reaction volume (0.5-1  mg of protein) with 2-20  ng of 
[r25I]CRMI97  at 24°C for 4  h  unless otherwise stated, with gentle shak- 
ing. Then the mixture was rapidly filtered on Millipore GVWP filters, and 
each filter was washed with 10 ml of cold Buffer D. The amount of radioac- 
tivity retained on each filter was counted in a "/-counter.  Nonspecific binding 
was assessed in the presence of a  1,000-fold  excess of unlabeled CRMI97. 
Solubilization  of CRMl97-binding  Activity from 
Isolated Membrane and a Column Assay 
Vero cell membranes were suspended with Buffer A at a protein concentra- 
tion of 10 mg/ml, and solubilized by addition of 1 M  octylglucoside to a 
final concentration of 60 mM. The mixture was incubated for 30 rain on 
ice and then centrifuged at 80,000 g for 30 rain to remove insoluble material. 
The supernatant (100 ~1) was incubated with 3 Ixl of [~25I]CRM197 (15 ng, 
1.5-2  ×  107 cpm/~tg) at 4°C for 6-14 h. An aliquot (70 ltl) of the mixture 
was applied to a Sephadex G-150 column (190 ×  7 ram), eluted with Buffer 
A containing 15 mM octylglucoside, and  ll0-p_l  fractions were collected. 
The radioactivity in 50 ~tl of each fraction was determined with a `/-counter. 
The amount of nonspecific binding was determined by the addition of 1,300- 
fold excess unlabeled CRM197. To determine total binding and nonspeciflc 
binding under the same conditions, we carried out the experiments at the 
same time using two columns of the same size. 
Dot Blot Assay of CRM197-binding Activity 
Each fraction of solubilized Veto cell membrane eluted from CM-Sepharose 
was diluted to 10%  with buffer containing 0.1 M  Tris and 0.19 M  glycine, 
pH 9.0, and blotted onto nitrocellulose filters. Two identical blot sets were 
set.  The filters were soaked in blocking solution (0.15  M  NaCI,  10 mM 
phosphate buffer,  l0 mg/ml BSA, 4.5  mg/ml fish gelatin, 5 mg/ml lyso- 
zyme, pH 7.2) at room temperature overnight, and then in Buffer D contain- 
ing 0.05%  Tween-20 at 37°C for  1 h.  One of the filters was treated with 
100 ng/ml of [~25I]CRM197 in Buffer D containing 0.5% Tween-20, while 
the other filter  was treated  with  the same amount of [~25I]CRM197 and 
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Figure 1. Inhibition of DT-cy- 
totoxicity by membrane  frac- 
tions of DT-sensitive and DT- 
insensitive cells. FL cells were 
incubated for 2 h at 37°C with 
DT  (40  ng/ml)  and  various 
amounts  of membrane  frac- 
tions from cultured cells. Then 
the  cells  were  labeled  with 
[3H]leucine for  1 h at  37°C, 
and the rate of protein synthe- 
sis was measured. The inhibi- 
tory activity was calculated as described in Materials and Methods. 
The control  values of protein synthesis with DT and without DT 
were 1,200 and 12,500 cpm, respectively. The membrane fractions 
with 1 mg protein from Vero  cells, L cells, HeLa cells and Ehrlich's 
ascites tumor cells contained 16.6 ~tg, 12.0 I.tg, 29.0 p.g and 10.6 Ixg 
of RNA,  respectively.  (e)  Vero cell  membrane;  (t2) HeLa cell 
membrane;  (r,) L cell membrane;  (m) Ehrlich's ascites tumor cell 
membrane. 
100 I.tg/ml of unlabeled CRM197  in the same buffer.  After incubation at 
24°C  for 5  h,  the filters were washed five times with buffer containing 
0.3 M NaCI, 10 mM MES, 0.05% Tween-20, pH 6.2. The filters were dried 
and autoradiographed using Fuji X-ray  film. 
Radioiodination  and lmmunoprecipitation 
of  DT Receptor 
A fraction (200 lal) of DT receptor eluted from CM-Sepharose was radioio- 
dinated by 0.5 mCi Bolton-Hunter reagent with 50 mM borate buffer,  pH 
9.1. The labeled sample (1.1  x  l0  ~ cpm) was incubated at 4°C for 14 h 
with DT or one of the CRM proteins at the concentration indicated dissolved 
in immunoprecipitation buffer (0.3  M  NaCl, 50 mM MES,  10 mM KCI, 
0.5 mM CaCI2,  l  mg/ml BSA, l  mg/ml ovalbumin, l  mg/ml lysozyme, 30 
mM octylglucoside, 0.01% SDS, 0.5 mM PMSE pH 6.1). Followed by the 
addition  of  horse  anti-DT  antibody  conjugated  with  CNBr-activated 
Sepharose beads (20 I.tl). The mixture was incubated at 24°C for 5 h with 
gentle shaking. The Sepharose beads were pelleted, washed with buffer: 
0.3 M NaCl, lO mM phosphate buffer, 30 mM octylglucoside, 0.01% SDS, 
pH 6.1. The radioactivity of the pellet was counted by a ),-counter.  For analy- 
sis by SDS-PAGE, the pellet was suspended with 50 ktl of SDS gel sample 
buffer, boiled for 5 min. The supernatant wassubjected by SDS-PAGE un- 
der reducing or nonreducing condition as described (19). After electropho- 
resis the gels were fixed, dried and autoradiographed. 
Western Blot Analysis of  DT Receptor 
The DT receptor fraction from CM-Sepharose was concentrated "~10 times 
of the original volume and the buffer was replaced to SDS-gel sample buffer 
using a Molcut concentrator (Millipore, Bedford, MA). After incubation 
at 37°C for 3 h, two sets of protein samples were run on 15% SDS-PAGE 
and then transferred to Durapore filters (type GVHP, Millipore) using a 
electroblotting equipment. After treatment with the blocking solution, one 
of the filters was treated with l~25I]CRM197 and the other with []~51]CRM- 
197 plus 1,000 times excess unlabeled CRM197 according to the same con- 
ditions as described in dot blot assay. The filters were washed, dried, and 
autoradiographed. 
Results 
Cell Membranes Contain an Inhibitor 
of DT Cytotoxicity 
The Vero cell line is highly sensitive to DT (29).  We found 
that a membrane fraction isolated from Vero cells inhibited 
the cytotoxicity of DT. Addition of DT at 40 ng/ml to FL cell 
cultures reduced protein synthesis to '~10% of the value in 
control  cultures.  When  the membrane fraction was added 
with DT to FL cell cultures, the rate of cellular protein syn- 
thesis was increased in a dose-dependent manner, indicating 
that the cytotoxicity of DT was blocked (Fig.  1). The mem- 
brane fraction per se had no effect on cellular protein synthe- 
sis.  The inhibitory activity of the membrane was also ob- 
served when Vero cells were used in cytotoxicity assay, but 
~twofold higher amounts of membrane were required for a 
similar inhibitory effect. Thus, we used FL cells in the cyto- 
toxicity assay of DT in the following studies. 
We next tested whether membrane fractions isolated from 
other cell lines with different sensitivities to DT show inhibi- 
tion of the cytotoxicity.  HeLa cells are ,~100 times and mouse 
L cells ~105 times less sensitive than Vero cells (28).  Ehr- 
lich ascites tumor cells are more resistant than L cells (15). 
Fig. 1 shows that membrane fractions from all these cell lines 
inhibited the cytotoxicity of DT, indicating the inhibitor was 
present both in DT-sensitive and in DT-insensitive cell lines. 
Release of the Inhibitor  from Isolated Membrane and 
Chromatography on a DEAE-Ion Exchange Column 
The membrane fraction of Vero cells was treated with various 
concentrations of octylglucoside, and the inhibitory activity 
recovered in the supernatant after centrifugation was deter- 
mined.  The inhibitory activity was partially released with 
octylglucoside at a concentration 15 mM, and maximal re- 
lease was found at concentrations greater than 30 mM. 
The  solubilized  inhibitor  was  chromatographed  on  a 
DEAE-cellulose ionexchange column in the presence of 30 
mM octylglucoside. Inhibitory activity was observed in the 
fractions with  NaC1  concentrations  between  300  and  500 
mM. The fractions with inhibitory activity were mixed and 
used  for  further  characterization.  This  inhibitor  fraction 
with one unit of inhibitory activity contained 0.38 lag protein 
and  1.84 lag RNA. 
DT Inhibitor Binds to DT but not to CRM197 
We examined whether the inhibitor could bind to DT.  The 
inhibitor  was  incubated  with  Sepharose beads  conjugated 
with DT or BSA.  The gels were washed and the inhibitor 
bound to gels was eluted with 4 M KSCN. When the inhibi- 
tor was incubated with DT-beads, '~95 % of the initial inhibi- 
tory activity was bound to the beads. With BSA-beads only 
a  trace amount was adsorbed to the beads (Table I). 
Next we determined the region of DT responsible for the 
binding of the inhibitor. To do this, we used DT fragment A 
and CRMs.  CRM45  is a premature termination protein of 
DT containing enzymatically active fragment A  and about 
half of the B fragment (43). As shown in Table I, the inhibitor 
was not bound to beads conjugated with fragment A or with 
CRM45,  indicating that at least the COOH-terminal  15-kd 
region  of  DT  is  required  for  binding  of  the  inhibitor. 
CRM197 is a product ofa missense mutation in the DT gene 
(44) and differs from wild type toxin only in one amino acid 
residue in fragment A (8). CRM197 is known to bind to DT- 
sensitive cells with an affinity similar to or higher than that 
of native toxin (25).  Interestingly, the inhibitor was not ad- 
sorbed with CRM197-beads. Therefore, not only fragment B 
but also fragment A  is required  for the binding of the in- 
hibitor. 
Effect of  the Inhibitor on the Binding of  DT and CRMs 
to Vero Cells 
The effects of the inhibitor on the b!nding of DT and CRM 
Mekada et al.  Receptor and Inhibitor of Diphtheria Toxin  513 Table L Adsorption of  the Inhibitor onto Sepharose beads Conjugated with DT or Related Proteins 
Protein 
conjugated 
to beads  Not retained by gel 
Percentage of total  inhibitory activity recovered 
Retained by gel 
DT  4.9  95.1 
BSA  99.5  0.5 
DT  1.0  99.0 
CRM45  96.8  3.2 
Fragment A  96.4  3.6 
DT  11.6  88.4 
CRM 197  90.1  9.9 
DT inhibitor purified  using a DEAE-cellulose column (1  ml, 20 U of the inhibitory activity)  was incubated with Sepharose beads conjugated with DT or the 
related pro~ins for 2.5 h at 37"C. After washing with Buffer B containing 0.3 M NaCI, the inhibitor bound to gels was eluted with 4 M KSCN. After dialysis, 
samples of Sepharose-unbound fraction and Sepharose-bound fraction were serially diluted, and the inhibitory activity in each diluted sample was determined. 
proteins to Vero cells were examined by an indirect binding 
assay using a  ~25I-labeled monoclonal antibody against DT 
(25).  This antibody, referred to as No. 2, binds to DT but 
does not inhibit the binding of DT to cells (10).  As shown 
in Fig. 2, the inhibitor blocked the binding of DT to Vero  cells 
but not the binding of CRM197. This was also confirmed by 
a direct binding assay using [~25I]DT or [t25I]CRM197  (data 
not  shown).  Moreover,  the  indirect binding  assay showed 
that  the  inhibitor  blocked  the  binding  of  CRM176  and 
CRM228 to the cells (Fig. 2). It is known that several nucleo- 
tides containing ATP bind to DT (1,  5,  21) and inhibit the 
binding of DT to cells (31, 34). However, ATP does not bind 
to CRM45 or CRM197 (22). We have shown (25) that ATP 
inhibited the binding of CRM176 and CRM228 to Vero cells, 
but not the binding of CRM197. The effects of the inhibitor 
on binding of DT and CRMs to Vero cells are very similar 
to those of ATP. 
Inhibitory Activity Is Destroyed by RNase 
To investigate the chemical properties of the inhibitor,  we 
treated the inhibitor with various enzymes, and measured the 
remaining  inhibitory  activity.  The  similarity  between  the 
effects of the inhibitor and those of ATP or other nucleotides 
on the binding of DT and CRMs suggested that the inhibitor 
might have a nucleotide-like structure. Therefore, we treated 
the inhibitor with several RNases and the remaining inhibi- 
tory  activity  was  measured.  As  no  suitable  inhibitor  for 
RNase was available,  we also carried  out control  experi- 
ments for each enzyme in which the same amount of enzyme 
IOC,  • 
1t,5 
0  10 
inhibitor  (Ulml) 
Figure 2. Effect of DT inhibi- 
tor on the  binding  of DT or 
CRMs to Vero cells measured 
by an  indirect  binding  assay 
using  t25I-anti-DT antibody. 
~25I-Antibody was  incubated 
with DT or CRMs. The mix- 
ture  and  various  amounts  of 
DT  inhibitor  were  added  to 
Vero cells, and the cells were 
incubated for 90 min at 37°C. 
Then  specific  cell-associated 
radioactivity  was  measured. 
(e)  DT;  (A)  CRM197; (,,) 
CRMI76; (r3) CRM228. 
alone was added to FL cell cultures in the DT cytotoxicity 
assay. The results are shown in Table II. The inhibitory activ- 
ity was  not affected by RNase T1,  but was  inactivated by 
RNase T2, RNase U2 or nuclease P1. RNase A was slightly 
effective. DNase I, II and Escherichia coli alkaline phospha- 
tase had no effect (data not shown). None of these enzymes 
alone influenced either cellular protein synthesis per se or 
the sensitivity of FL cells to DT. These results indicate that 
the  inhibitor  contains  a  poly-ribonucleotide structure  that 
is  required  for inhibitory  activity.  The  inhibitor  was also 
treated with trypsin or chymotrypsin, but these enzymes did 
not affect the inhibitory activity (Table II). 
As shown in Fig. 2, addition of the inhibitor at 0.3 U/ml 
(containing RNA at 0.55 Ixg/ml) shows 50 % inhibition on the 
binding ofDT. ATP was required at ,'~165 lxg/ml for the same 
effect (25).  Therefore, although the effects of the inhibitor 
and those of ATP on the binding of DT and CRMs are very 
similar, the inhibitor described here is much more effective 
than ATP. 
p25I]CRM197 Binds to Vero Cell Membrane but not to 
L Cell Membrane 
The inhibitor was present even in the membrane fractions of 
toxin-insensitive cells•  Moreover, although CRM197  binds 
to Vero cells with an affinity similar to, or greater than that 
of DT (25),  the inhibitor did not bind to CRM197 and did 
not inhibit the binding of CRM197 to Vero cells• These facts 
suggest that the inhibitor is not the receptor responsible for 
the difference in sensitivity to DT between species, and that 
another DT-binding substance would be present in the mem- 
brane of DT-sensitive cells.  If the membrane fraction from 
Vero cells contains two DT-binding substances, the inhibitor 
and the receptor, the inhibitor could prevent the binding of 
DT to  DT receptor  when  the binding  assay  is  performed 
using the membrane fraction. CRM197 did not bind the in- 
hibitor,  so  the  effect  of the  inhibitor  on  the  binding  of 
CRM197 to the DT receptor would be minimal.  Thus,  we 
used CRM197 to look for a DT receptor in Vero cell mem- 
brane preparations. 
Vero cell  membrane  was  incubated  with  [t25I]CRM197 
and then the radioactivity associated with the membrane was 
measured as described under  Materials  and  Methods.  As 
shown in Fig. 3, saturable specific binding of [~25I]CRM197 
was observed. Specific binding was increased with time and 
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Protein synthesis, percentage of control 
- Toxin  + Toxin  + Toxin 
Experiment  Enzyme  Concentration  -inhibitor  - inhibitor  + inhibitor 
1  No enzyme  100  11.9  89.1 
RNase T1  19 U/ml  104  10.6  82.1 
RNase A  30 p.g/ml  111  16.2  63.4 
RNA T2  5  U/ml  114  10.2  19.9 
Nuclease P1  20 lxg/ml  108  8.5  23.6 
2  No enzyme  100  19.4  78.9 
RNase T2  0.1  U/ml  ND  ND  50.0 
1  U/ml  ND  ND  28.1 
10 U/ml  ND  19.4  16.1 
3  No enzyme  100  9.6  66.0 
RNase U2  82 U/ml  ND  10.0  12.8 
4  No enzyme  100  15.6  84.6 
Trypsin  100 ~tg/ml  ND  16.1  79.8 
chymotrypsin  100 I.tg/ml  ND  16.3  71.6 
DT inhibitor purified by DEAE-cellulose column was dialyzed against PBS. The detergent-free inhibitor (100 lal, 10 units of the inhibitory activity) was incubated 
with each of the enzymes at the concentration indicated for 1 h at 37"C.  Remaining inhibitory activity was determined by the addition of 30 Ixl of enzyme-treated 
sample and DT to FL cell cultures. To measure the effect of the enzymes alone on cellular protein synthesis and sensitivity to DT, the equivalent concentration 
of the enzyme was added in the absence of the inhibitor. ND, not done. 
reached a maximum in 4 h. Analysis by Scatchard plots (37) 
indicates a  single class of binding sites with a Ka value of 
2.1  x  109 liter/mol (Fig. 3 B). This value is consistent with 
the value determined by us in intact Vero cells (25). 
We also examined the binding of [~25I]CRM197 to mouse 
L cell membrane. Over the range of CRM197 concentration 
used for Vero cells, no specific binding was observed (data 
not shown). Thus, the sites specific for CRM197 binding are 
either not present on DT-insensitive L cells, or exist in very 
low density to be detected in our binding assay. These results 
clearly show that the molecule which binds CRM197 differs 
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Figure  3.  Binding of various 
concentrations of [I~I]CRM197 
to  Vero  cell  membrane.  (A) 
Vero  cell  membrane  (200  lal 
containing  125  I.tg protein) 
was incubated at 24°C for 4 h 
with various concentrations of 
[IZsI]CRMI97 (2.5  ×  107 cpm/ 
gtg).  Then  150 gl of the mix- 
ture was removed and the ra- 
dioactivity associated with the 
membranes  determined.  (e) 
[125I]CRM197;  (It) [~25I]CRM- 
197  +  unlabeled  CRM197; 
(0) difference between •  and 
m.  (B)  Scatchard  plot of the 
specific binding of [125I]CRM- 
197  to  Vero cell  membrane. 
The  lines  were  fitted  by  re- 
gression analysis. 
from the  inhibitor,  because the  inhibitor exists on L  cell 
membrane in densities similar to those on Vero cell mem- 
brane. 
To examine whether the observed binding of [tz~I]CRM- 
197 to Vero cell membrane is truly specific for DT, we per- 
formed a competition assay using unlabeled DT or CRMs. 
As shown in Fig. 4, the binding of [~25I]CRM197 was most 
strongly inhibited by nicked CRM197. Native DT was about 
three times less potent and CRM228  was "~200 times less 
potent than  nicked CRM197.  CRM45  did  not inhibit the 
binding of labeled CRM197 (data not shown). These results 
strongly suggest that the binding sites for CRM197 observed 
in membrane fractions were DT receptors. 
Binding of p25I]CRMI97 to Solubilized Cell 
Membrane Components 
We next examined  the binding of [~25I]CRM197 to solubi- 
lized membrane components using a gel filtration method. 
.  100 
|.o 
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Figure 4. Competition for bind- 
ing  of  [t25I]CRM197  to  Vero 
cell membranes by unlabeled 
DT or unlabeled CRMs.  Vero 
cell membranes (200 lal con- 
raining  100  lag  protein)  was 
incubated at 24°C for 4 h with 
[J25I]CRM197  at  30  ng/ml 
(2.5  x  107 cpm/Ixg) and vari- 
ous  concentrations of one of 
the  unlabeled  protein.  The 
specific  radioactivity  associ- 
ated  with  Vero cell  membranes was  measured.  The data are ex- 
pressed as  a  percentage of the inhibition of the specific binding, 
which was 6,000 cpm.  (-)  Nicked CRMI97;  (e) nicked DT;  (D) 
CRM228. 
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Figure 5.  Column  assay  for 
the  binding  of [t25I]CRM197 
to solubilized membrane com- 
ponents.  [t25I]CRM197 was 
incubated with solubilized ma- 
terial  from  Vero cell  mem- 
brane (A) or L cell membrane 
(B) for 6 h at 4°C.  The mix- 
ture was applied to a Sephadex 
G-150 column.  The  radioac- 
tivity of each fraction was de- 
termined.  The broken  line is 
the  radioactivity  obtained  by 
incubation with [~25I]CRM197 
and excess unlabeled CRM197. 
Solubilized material from Vero cell membrane treated with 
60  mM  octylglucoside  was  incubated  with  [z25I]CRM197. 
The mixture was applied to a Sephadex G-150 column in the 
presence of detergent, and the radioactivity of each fraction 
was counted. The results are shown in Fig. 5 a. Two radioac- 
tive peaks were observed: the first at fraction No. 23 and the 
second at fraction No. 39. When excess unlabeled CRM197 
was added with [125IICRM197, the first peak did not appear 
(Fig.  5,  broken line). When  [125IICRM197  was  applied to 
the column in the absence of membrane components, the first 
peak did  not appear (data not shown).  We carried out the 
same experiment on solubilized material from L cell mem- 
branes. Although a tiny peak appeared around fraction No. 
25, significant differences were not observed when the mem- 
brane  material  was  incubated  with  ['25I]CRM197  only  or 
with  [~2-~I]CRM197 and excess unlabeled  CRMI97  (Fig.  5 
b).  Therefore, we concluded that the first peak seen in the 
Vero cell  experiments was  [~25I]CRM197 bound  to the  re- 
ceptor and  the  second  was unbound  CRM19Z  When  Vero 
cell membranes were treated with 30 mM octylglucoside, the 
receptor activity in soluble fraction was less. This is addi- 
tional evidence that the inhibitor and the receptor are differ- 
ent  substances because the  inhibitor  was released fully by 
treatment of membranes with 30 mM octylglucoside. This 
observation also indicates that the DT receptor can bind to 
CRM197  in the presence of detergent. 
Treatment of  the Receptor with Trypsin or RNase T2 
As  shown  above,  the  inhibitory  activity  was  destroyed  by 
some RNases, but norby protease. To compare the CRM197- 
binding substance, that is the receptor, with the inhibitor, we 
tested the effects of trypsin and RNase T2 on the CRM197- 
binding activity using the column assay. The results showed 
that  trypsin  destroyed  the  CRM197  binding  activity,  but 
RNase T2 had no effect. This is a  striking difference from 
the case of the inhibitor, and shows that the DT receptor has 
a  proteinaceous structure. 
Partial Purification of  DT Receptor 
The  solubilized  Vero cell  membrane  material  was  chro- 
matographed on a  ion-exchange column.  When  the  mem- 
brane material was applied on a DEAE-cellulose column un- 
der  conditions  similar  to  that  for  the  purification  of DT 
inhibitor, CRM197-binding activity was detected in the flow- 
through  fraction.  On  a  CM-Sepharose  column,  CRM197- 
Figure 6.  Dot-blot analysis of CRM197-bind- 
ing activity  in CM-Sepharose  fractions.  The 
solubilized Vero  cell membrane materials (300 
mg  protein)  were  applied  to  CM-Sepharose 
column (1.1 x  8 cm). The proteins were eluted 
with  a  linear  gradient  of NaCI  (0.2-1 M)  in 
10 mM phosphate  buffer, pH 7.0, containing 
0.5  mM CaCI2, 30 mM octylglucoside.  Each 
fraction  was spotted on nitrocellulose  filters. 
The filter was probed  with  100  ng/ml  [~25I]- 
CRMI97  (A), or  100  ng/ml  [125I]CRM197 
plus  100 lag/ml unlabeled CRMI97 (B).  The 
specific CRM197-binding activity was seen in 
fractions 6 to 9. 
binding activity was retained on the column and found to be 
eluted with 0,4-0.6 M NaCI (Fig. 6). For this sample dot-blot 
assay was performed for the measurement of CRM197-bind- 
ing activity. The specific CRM197-binding activity was seen 
in  fractions 6-9,  corresponding to  eluates with 0.4-0.6  M 
NaCI.  These  fractions  were  mixed  and  used  for  further 
studies. 
Protection of  DT Cytotoxicity by DT Receptor 
The protective effect of soluble DT receptor was tested by ad- 
dition of the excess amounts of receptor to a cell and DT mix- 
ture. We tested this using the CM-Sepharose fraction of DT 
receptor, because this fraction did not contain the inhibitor. 
As shown in Table III, DT receptor fraction protected the tox- 
icity of DT. 
Identification of  DT Receptor 
The  CM-Sepharose  fraction  containing  DT  receptor  was 
radioiodinated and immunoprecipitated using either DT or 
other  CRM  proteins  and  immobilized  anti-DT  antibody. 
When the  iodinated material was incubated with CRM197 
Table IlL Protection of  DT Cytotoxicity by DT Receptor 
The rate of protein synthesis 
(Percentage  of control) 
Receptor sample added 
Experiments  0  100  p.I  250  Ixl 
1  9.5  28  49 
2  38  63  83 
Partially  purified DT receptor by CM-Sepharose was mixed with 1 mg/ml BSA 
and  the  mixture  was dialyzed  against  leucine-diminished  MEM.  500  ttl  of 
MEM containing 10% leucine and  I mg/ml BSA and the indicated volume of 
dialyzed  receptor fraction was incubated with DT (1  ng/ml) at 37°C  for 30 
min. The mixtures were added to Vero cell cultures and incubated at 37°C for 
2 h,  followed by incubation with 2  ~tCi/ml  [3H]leucine  at 37°C for  I  h.  The 
radioactivity  incorporated in proteins was determined and the rate of protein 
synthesis was expressed as a  percentage of that  in cultures containing same 
amounts of the receptor without DT. 
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Figure 7.  IYl'-specific precipi- 
tation of radioiodinated mem- 
brane proteins. The radioiodi- 
nated material containing DT 
receptor  was  incubated  with 
DT or one of the CRM pro- 
teins at the concentrations in- 
dicated,  and then further incu- 
bated  with  anti-IYr antibody 
conjugated  with  Sepharose 
gels. In some samples, ATP (2 
mM) or the inhibitor isolated 
here (15 U/ml) was added with 
DT and CRM197.  The radio- 
activity associated to gels was counted.  The results are expressed 
as a percentage of total radioactivity added. The symbols indicate: 
CRMI97  (zx); DT  (o):  CRM45  (~z); fragment A  (n):  CRM197 
with ATP (-); DT with ATP (e); CRMI97 with the inhibitor (v) 
and DT with the inhibitor (-). 
and anti-DT antibody, the radioactive material was precipi- 
tated by CRM197  in a  dose-dependent  manner (Fig.  7).  A 
similar result was obtained using DT and anti-DT antibody, 
but the precipitate of the radioactive materials was lower than 
that in the case of CRM197.  With CRM45 or with fragment 
A  of DT no significant precipitation  was observed even at a 
concentration of 500 ng/ml. To test whether the immunopre- 
cipitation is properly specific for DT receptor, we used ATP 
or  DT  inhibitor.  The  addition  of DT  inhibitor  (15  U/ml) 
strongly decrease the specific precipitation by DT, while the 
precipitation  by CRM197  was slightly  affected with the in- 
hibitor.  ATP  also  showed  a  similar  result.  These  findings 
strongly suggest that the precipitation is DT receptor specific. 
The  immunoprecipitated  materials  were  analyzed  by 
SDS-PAGE.  In  the  samples  precipitated  with  DT  or 
CRM197 and anti-DT antibody, three major bands with mo- 
lecular  masses  of  14.5,  47,  and  62  kD  and  several  minor 
bands are seen in a reducing condition (Fig.  8 A, lanes 2 and 
4,  respectively).  When neither DT nor CRM197  was added 
(lane 1), or DT and a  nonspecific antibody was added (lane 
6),  such major three bands  were not seen.  By the addition 
of ATP in the precipitation procedure with DT, the three ma- 
jor bands and some of the minor bands were greatly dimin- 
ished (lane 3). However, ATP did not affect the precipitation 
with CRM197  (lane 5).  Similar results were obtained in the 
case of DT inhibitor.  Under nonreducing  conditions,  a band 
with more than  100 kD appeared,  the density of the 47-kD 
and the 62-kD bands was diminished.  The mobility of 14.5- 
kD protein did  not change under  nonreducing  conditions. 
Although the results of immunoprecipitation study suggest 
that the three major proteins seen on SDS-PAGE are related 
to DT receptor, there is the possibility that the receptor co- 
precipitated with contaminating cellular materials.  As addi- 
tion of ATP or the inhibitor caused global reduction  of the 
immunoprecipitates  with DT, we could not identify specific 
protein  band(s)  responsible  for  DT  binding.  To  identify 
which molecule on SDS-PAGE has the property to bind to 
DT,  we carried  out a  Western blot analysis  of the  receptor 
fraction eluted  from CM-Sepharose  using  [125I]CRM197 as 
probe. As shown in Fig. 9, only a single band with a molecu- 
lar mass of 14.5  kD was observed.  This band was identical 
to the  14.5-kD  band  seen  in  immunoprecipitation  study of 
Fig. 8, judged by its mobility on an SDS gel. When the probe 
contained  an  excess  amount  of  unlabeled  CRM197,  no 
significant  bands  were  observed.  Thus  we  concluded  that 
this 14.5-kD band is the DT receptor or at least a component 
of it.  This finding also suggested that  14.5-kD DT receptor 
is associated with the 47- and the 62-kD proteins,  and these 
proteins  were  co-precipitated  by  the  addition  of  DT  or 
CRM197  and  the antibody. 
Discussion 
We have shown that an inhibitor present in a membrane frac- 
tion  of  cultured  cells  blocks  the  cytotoxicity  or  DT  by 
preventing its binding to target cells. RNase treatment of the 
inhibitor  revealed  that  the  ribonucleotide  structure  is  in- 
Figure 8. Immunoprecipitates of the partially purified DT receptor 
fraction were analyzed by SDS-PAGE.  DT receptor fraction was 
radioiodinated  and  precipitated  with  DT  or  CRM  proteins  and 
anti-DT  antibody.  The  precipitated  proteins  were  run  on  SDS- 
PAGE (15 % gel) in the presence (A) or absence (B) of dithiothreitol 
(DTT) and  autoradiographed.  (Lane  1)  Anti-DT  antibody only; 
(lane  2)  DT  (300  ng/ml)  and  anti-DT  antibody;  (lane  3)  ATP 
(2 mM) with  DT and anti-DT antibody;  (lane 4)  CRM197  (300 
ng/ml) and anti-DT antibody; (lane 5) ATP (2 mM) with CRM197 
and anti-DT antibody; (lane 6) DT and control antibody; (lane 7) 
total  ~25I-labeled material.  The  14.5-kD bands are shown by ar- 
rows and the 47- and 62-kD bands are shown by arrowheads. 
Figure 9.  Western  blot analy- 
sis of DT receptor.  The sam- 
ples  of partially purified  DT 
receptor (used 10 Ixl for lanes 
2 and 4, and 30 Ixl for lanes 3 
and  5)  were  run  on  SDS- 
PAGE  (15%  gel)  and  trans- 
ferred  to  two  sets  of filters. 
One  filter  was  probed  with 
100 ng/ml  125I-CRM197 (lanes 
2 and 3),  the other with  100 
ng/ml  ~25I-CRM197  in  the 
presence of 100 Ixg/ml of unla- 
beled  CRMI97  (lanes  4  and 
5). The filters were dried and 
autoradiographed.  Lane 1  is molecular markers containing  lyso- 
zyme (14,300),  carbonic anhydrase (30,000),  ovalbumin (46,000), 
BSA (69,000)  and phosphorylase b (92,500).  The  14.5-kD bands 
are shown by arrows. 
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dinucleotides,  such  as  adenyl-(Y,5')-uridine-Y-monophos- 
phate (ApUp), bind to DT (5). ATP is known to bind to DT 
(21) and inhibit its cytotoxic activity (30). Thus the inhibitor 
may inhibit the cytotoxicity of DT by a mechanism similar 
to that of the above mentioned nucleotides. We suggest that 
the inhibitor is not a molecule with a specific role in the bind- 
ing DT to the surface of DT-sensitive cell, the reasons are as 
follows: (a) the inhibitor was found in DT-insensitive cells, 
(b) the inhibitor did not bind to CRM197 and (c) the affinity 
of the inhibitor for DT appeared to be lower than the affinity 
of DT receptor for DT. 
Does the inhibitor exist on the cell surface? The plasma 
membrane-rich fraction used in this paper contained inner 
membranes,  and RNA  from the cytoplasm may associate 
with  inner  membranes.  To  clarify  whether  the  inhibitor 
comes from the surface of the plasma membrane or from in- 
ner membrane components, we treated Ehrlich ascites tumor 
cells with RNase T2 or RNase U2 and then isolated the mem- 
brane  fractions.  Membranes  isolated  from  such  RNase- 
treated and untreated cells showed similar inhibitory activi- 
ties for DT-mediated cytotoxicity. Although this finding may 
indicate that the inhibitory substance mainly exists on inner 
membranes,  it was  not clear whether RNases  used  were 
effective for the inhibitor on the cell surface of intact cells. 
Therefore, we could not show any direct evidence on location 
of the  inhibitor.  However, Keen et al.  (16)  observed that 
fluorescently labeled DT binds to and is  internalized into 
mouse cells when the toxin is added at relatively high con- 
centrations, indicating that binding sites for DT are present 
on the surface of DT-insensitive cells. Weiss and Mayhew 
(23, 47) reported that RNA is a structural component of the 
cell surface membrane based on observations made on the 
mobility of cells after RNase treatment and electrophoresis. 
Terasaki et al.  (41) using antibody against single-stranded 
RNA confirmed the existence of RNA on the cell surface. 
These facts support the existence of the inhibitor on the cell 
surface. The inhibitor reported in this study may be derived 
from both the inside and the outside of cells. 
The second DT-binding molecule present in the membrane 
fraction has characteristics of the surface receptor for DT. 
This molecule actually defines the sensitivity of cells to DT 
in different species. In fact, (a) this substance is present only 
in DT-sensitive cells, (b) it binds to CRM197, and its binding 
affinity is similar to that obtained with intact Vero cells. Fur- 
thermore,  the  results  of the  competition  experiments  in 
which binding of [t25I]CRM197 to Vero cell membrane was 
measured in the presence of DT and various CRMs are con- 
sistent with CRM197 binding experiments with intact Vero 
cells. Therefore, we conclude that this binding activity is due 
to the DT receptor present in  DT-sensitive cells.  Specific 
binding of DT to the receptor has not been reported using iso- 
lated membrane or a  solubilized membrane fraction.  The 
presence of the inhibitor might have interfered in the binding 
of DT to its receptor and made the interpretation of such ex- 
periments hard. Using ~25I-labeled CRM197 we could dem- 
onstrate DT receptor in a crude solubilized membrane frac- 
tion by a column assay and in a partially purified fraction by 
a dot blot assay. The immunoprecipitation study and Western 
blot analysis revealed a protein of 14.5 kD in SDS-PAGE, 
we think this molecule is the DT receptor or a component 
of it.  Furthermore,  it was  clear by Western blot analysis 
probed  with  the  labeled  CRM197  that  the  14.5-kD  pro- 
tein is the molecule directly binding DT. This conclusion is 
supported  by  other  evidence:  using  cross-linking  agents, 
Cieplak et al. (3) recently suggested that a 10--20-kD cell sur- 
face protein(s) is, or constitutes a portion of DT receptor. Is 
this  14.5-kD protein a functional DT receptor? As DT-DT 
receptor complexes appeared  in  the  void  fraction of the 
column assay, using Sephadex G-150 column and crude solu- 
bilized membranes (Fig. 5), it is possible that the 14.5-kD 
proteins form aggregates in membrane prior to solubiliza- 
tion. Of course, the possibility that  14.5-kD protein was a 
processed form of the precursor or a native molecule cannot 
be ruled out. As shown in Fig. 8, two proteins with molecular 
weights of 47 and 62 kD precipitated prominently with 14.5 
kD protein when separated under reducing conditions. These 
molecules are seen to form one bigger molecule under non- 
reducing conditions. These proteins may also be related to 
DT receptor, but much more extensive studies will be re- 
quired to elucidate the relationship of these components to 
the DT receptor. 
It is unclear whether the inhibitor plays any role in DT in- 
toxication. However, we think it may. First, the inhibitor may 
act as a second receptor on DT-sensitive cells. It may serve 
to draw the DT molecule more closely to lipid bilayer, or the 
binding of DT to the second receptor may lead to a change 
in the conformation of the DT molecule to expose a hydro- 
phobic region. The receptor site and inhibitor site on the DT 
molecule may be close together or overlapped. If the inhibi- 
tor is added exogenously, the inhibitor binds and covers the 
receptor site or causes a conformational change, resulting in 
inhibition of the binding to the receptor. The second possible 
role of the inhibitor is in the passage of the toxin from an en- 
docytotic vesicle to the cytoplasm through the lipid bilayer. 
A RNA-protein complex, called signal recognition particle, 
is known to be essential for the translocation of newly synthe- 
sized proteins to the  luminal  sides  of rough endoplasmic 
reticulum (46). Like the signal recognition particle the inhib- 
itor may play some role in translocation of macromolecules 
into the cytoplasm. As CRM197 does not bind to the inhibi- 
tor, the function of the inhibitor may be revealed when the 
fate of CRM197 is analyzed more precisely. Finally, even if 
the inhibitor has no function in DT entry, the fact that this 
DT-binding molecule is present in membrane fractions must 
be taken into account in attempts to isolate the DT receptor. 
As CRMI97 does not bind to the inhibitor, CRM197 may be 
useful for the purification of the DT receptor. 
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